Drugs / V-01-B5
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05585567 | Sep → Oct 2022 | COVID-19 | Livzon Pharmaceutical Group Inc. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | V-01-B5 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05585567 ↗ |
| Modality | Vaccine | “Recombinant SARS-CoV-2 Fusion Protein bivalent Vaccine V-01-B5” NCT05585567 ↗ |